【摘要】 目的观察蒙药清肝九味散对酒精性肝炎患者的治疗作用。方法收集内蒙古民族大学附属医院2014年5月-2016年4月收治的酒精性肝炎患者63例,随机分为试验组(32例)和对照组(31例)。试验组给予蒙药清肝九味散治疗;对照组31例给予还原型谷胱甘肽片治疗。2组患者均治疗4周并在此期间均严格戒酒、卧床休息。计量资料组间比较采用t检验。结果对照组患者肝功能指标(ALT、AST、GGT)治疗后与治疗前比较均有明显改善[(38.7±13.3)U/L vs(77.5±16.7)U/L)、(43.8±21.8)U/L vs(176.6±40.1)U/L、(63.8±21.7)U/L vs(302.9±73.3)U/L,t值分别为10.21、16.90、17.40,P值均<0.01];试验组患者治疗后与治疗前比较亦有明显改善[(37.6±14.6)U/L vs(78.1±17.5)U/L、(39.6±15.3)U/L vs(180.3±44.3)U/L、(59.9±23.8)U/L vs(304.7±66.5)U/L,t值分别为10.10、16.40、19.60,P值均<0.01]。对照组患者血清中肝纤维化指标(透明质酸、Ⅲ型前胶原、层黏连蛋白、Ⅳ型胶原)治疗后均较治疗前明显改善[(122.1±36.2)ng/ml vs(369.2±139.8)ng/ml、(118.6±43.8)ng/ml vs(185.9±92.7)ng/ml、(137.2±49.9)ng/ml vs(166.1±50.4)ng/ml、(128.7±48.3)ng/ml vs(155.1±44.5)ng/ml,t值分别为9.52、3.66、2.24、2.27,P值均<0.05];试验组患者治疗后与治疗前比较亦有明显改善[(101.1±27.9)ng/ml vs(367.4±149.7)ng/ml、(91.6±48.4)ng/ml vs(188.3±100.5)ng/ml、(94.8±34.6)ng/ml vs(167.6±48.7)ng/ml、(92.7±30.3)ng/ml vs(161.3±62.2)ng/ml,t值分别为9.88、4.95、5.61、6.87,P值均<0.01]。2组间治疗后肝纤维化指标比较差异均有统计学意义(t值分别为2.53、2.31、3.56、3.90,P值均<0.05)。结论蒙药清肝九味散可以改善酒精性肝炎患者的肝功能,降低肝纤维化指标。更多还原

【Abstract】 Objective To investigate the clinical effect of Mongolian drug Qinggan Jiuwei powder in the treatment of patients with alcoholic hepatitis. Methods A total of 63 patients with alcoholic hepatitis who were admitted to Affiliated Hospital of Inner Mongolia University for The Nationalities from May 2014 to April 2016 were enrolled. The 32 patients in the trial group were given Mongolian drug Qinggan Jiuwei powder,and the 31 patients in the control group were given reduced glutathione tablets. The course of treatment was 4 weeks for both groups,and the patients were asked to quit drinking,stay in bed,and have a rest. The t-test was used for the comparison of continuous data between groups. Results After treatment,the control group showed significant improvements in the liver function parameters alanine aminotransferase( ALT),aspartate aminotransferase( AST),and gamma-glutamyl transpeptidase( GGT)( ALT: 38. 7 ± 13. 3 U / L vs 77. 5 ±16. 7 U / L,t = 10. 21,P < 0. 01; AST: 43. 8 ± 21. 8 U / L vs 176. 6 ± 40. 1 U / L,t = 16. 90,P < 0. 01; GGT: 63. 8 ± 21. 7 U / L vs 302. 9 ±73. 3 U / L,t = 17. 40,P < 0. 01); the trial group also showed significant improvements in these parameters( ALT: 37. 6 ± 14. 6 U / L vs78. 1 ± 17. 5 U / L,t = 10. 10,P < 0. 01; AST: 39. 6 ± 15. 3 U / L vs 180. 3 ± 44. 3 U / L,t = 16. 40,P < 0. 01; GGT: 59. 9 ± 23. 8 U / L vs304. 7 ± 66. 5 U / L,t = 19. 60,P < 0. 01). After treatment,the control group showed significant improvements in the serum liver fibrosis parameters hyaluronic acid,precollagen type Ⅲ,laminin,and collagen type Ⅳ( hyaluronic acid: 122. 1 ± 36. 2 ng / ml vs 369. 2 ± 139. 8ng / ml,t = 9. 52,P < 0. 05; precollagen type Ⅲ: 118. 6 ± 43. 8 ng / ml vs 185. 9 ± 92. 7 ng / ml,t = 3. 66,P < 0. 05; laminin: 137. 2 ±49. 9 ng / ml vs 166. 1 ± 50. 4 ng / ml,t = 2. 24,P < 0. 05; collagen type Ⅳ: 128. 7 ± 48. 3 ng / ml vs 155. 1 ± 44. 5 ng / ml,t = 2. 27,P <0. 05); the trial group also showed significant improvements in these parameters( hyaluronic acid: 101. 1 ± 27. 9 ng / ml vs 367. 4 ± 149. 7ng / ml,t = 9. 88,P < 0. 01; precollagen type Ⅲ: 91. 6 ± 48. 4 ng / ml vs 188. 3 ± 100. 5 ng / ml,t = 4. 95,P < 0. 01; laminin: 94. 8 ± 34. 6ng / ml vs 167. 6 ± 48. 7 ng / ml,t = 5. 61,P < 0. 01; collagen type Ⅳ: 92. 7 ± 30. 3 ng / ml vs 161. 3 ± 62. 2 ng / ml,t = 6. 87,P < 0. 01).There were significant differences in the liver function parameters after treatment between the two groups( t = 2. 53,2. 31,3. 56,and 3. 90,all P < 0. 05). Conclusion The Mongolian drug Qinggan Jiuwei powder can improve liver function and reduce liver fibrosis parameters in patients with alcoholic hepatitis.更多还原